General MedicationsTRANSDERMALGeneric
ADLARITY
DONEPEZIL HYDROCHLORIDE
Standard Dose
10MG/DAY
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview ADLARITY is listed in Drugs@FDA under application 212304 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient DONEPEZIL HYDROCHLORIDE Form and strength SYSTEM;TRANSDERMAL - 10MG/DAY Sponsor CORIUM Submission history Latest submission status date: 2022-03-11 00:00:00.
Structured Monograph
Clinical summary
Approval overview ADLARITY is listed in Drugs@FDA under application 212304 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DONEPEZIL HYDROCHLORIDE Form and strength SYSTEM;TRANSDERMAL - 10MG/DAY Sponsor CORIUM Submission history Latest submission status date: 2022-03-11 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.